Cost-effectiveness of enfortumab vedotin in previously treated advanced urothelial carcinoma.

ABSTRACT:

Background

Antibody-drug conjugates have recently been introduced as a treatment for advanced urothelial carcinoma. The EV-301 study demonstrated that enfortumab vedotin (EV) improved overall survival compared with conventional chemotherapy. To assess the cost-effectiveness of EV for the treatment of advanced urothelial carcinoma (UC) from a payer perspective in middle- and high-income countries.

Methods

A decision analysis model was developed to assess the efficacy and economic viability of EV as a subsequent-line treatment following disease progression in patients with advanced urothelial carcinoma already treated with PD-1 or PD-L1 inhibitors. Clinical and utility values were obtained from the published literature and available databases. Cost data were obtained from paye

SUBMITTER: Wu Q 

PROVIDER: S-EPMC8796084 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature